Search

Your search keyword '"Sweet Syndrome prevention & control"' showing total 2 results
Start Over Descriptor "Sweet Syndrome prevention & control"
2 results on '"Sweet Syndrome prevention & control"'

1. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.

Author

Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, and Tiu RV

Subjects
Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic adverse effects, Antimetabolites, Antineoplastic therapeutic use, Azacitidine administration & dosage, Azacitidine analysis, Azacitidine therapeutic use, Decitabine, Dose-Response Relationship, Drug, Humans, Injections, Subcutaneous, Male, Middle Aged, Primary Myelofibrosis complications, Risk Factors, Sweet Syndrome chemically induced, Sweet Syndrome complications, Treatment Outcome, Azacitidine adverse effects, Azacitidine analogs & derivatives, Primary Myelofibrosis drug therapy, Sweet Syndrome prevention & control
Published
2014
Full Text
View/download PDF

2. Sweet-like syndrome induced by bortezomib.

Author

Kolb-Mäurer A, Kneitz H, and Goebeler M

Subjects
Adrenal Cortex Hormones therapeutic use, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Boronic Acids therapeutic use, Bortezomib, Drug Eruptions prevention & control, Humans, Male, Multiple Myeloma complications, Pyrazines therapeutic use, Sweet Syndrome prevention & control, Treatment Outcome, Boronic Acids adverse effects, Drug Eruptions etiology, Drug Eruptions pathology, Multiple Myeloma drug therapy, Pyrazines adverse effects, Sweet Syndrome chemically induced, Sweet Syndrome pathology
Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results